Moleculin Biotech, Inc. · NASDAQ:MBRX
Moleculin Biotech — Investor Presentation (January 2022)
20 slides from Moleculin Biotech's investor presentation, Jan 10, 2022
Slide 1: Moleculin Investor Presentation
= Moleculin Better Treatments, More Tomorrows INVESTOR PRESENTATION / JANUARY 10, 2022 MOLECULIN.COM / NASDAQ: MBRX.
Slide 2: Disclaimer
Disclaimer All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial postion, our business strategy and plans, and our objectives for future operations, are forward-looking statements, The words “believe,”
Slide 3: Investment Highlights
Investment Highlights Advancing growing pipeline of clinical programs for the treatment of highly resistant cancers and viruses Annamycin Pipeline Expansion Next generation non-cardiotoxicanthracycline Success in lead program fuels pipeline demonstratingboth safety and promising preliminary possible
Slide 4: Priority Development Pipeline
Priority Development Pipeline PROGRAM INDICATION PRECLINICAL PHASE PHASE? UPCOMING MILESTONES Phase 1b/2 interim data demonstrated CLD preliminary clinical activity; Completion Sor Tiss of Phase 1b portion targeted H1 2022 Sarcoma Lung Mets qr, Phase 1b/2 study in Poland expected to commence Qi 2022
Slide 5: Management Team with Proven Executional Expertise
Management Team with Proven Executional Expertise Don Picker, PhO Jonathan P. Foster, CPA, COMA Chit Science Officer xectivn Vie President Chit Financial Officer Lac Eigt Sr Deloitte. 1, MD, FACP Chief Maal Offer @D vee @ Gad» FON Tots ®Moleculin
Slide 6: Leveraging the Brightest Scientific Minds
Leveraging the Brightest Scientific Minds / Pho > ConcerCenter HEMATOLOGY a p> ‘ir es00.00 | BH seems Marty Tallman, MD ‘Memorial Sloan Kettering PANCREATIC — James Abbruzzese, MD @ enaarder Duke Uiversiy Ween otesne orn Jorge Cortes, MD georsia B fenren VIROLOGY comes Richard Whitley, MD UCse ®Mole
Slide 7: Annamycin: Potential to be an Effective Treatment Across Multiple Oncology Indications
Annamycin: Potential to be an Effective Treatment Across Multiple Oncology Indications Target Indications: * Clinical Highlights + 2 ongoing Phase 1/2 clinical studies with data expected in 2022 + Demonstrated preliminary positive data in STS and AML 130,000 cases worldwide? SCE 20% to S0% of sarcom
Slide 8: Annamycin: Next Generation Anthracycline
BE Annamycin Next Generation Anthracycline Demonstrated to be Non-Cardiotoxict + Ability to overcome multi-drug resistance * >30x greater accumulation in lungs than doxorubicin * Potent topoisomerase-Il poison with a wider therapeutic window than doxorubicin? * <10% incidence of alopecia compared wi
Slide 9: Ongoing Phase 1b/2 Study for Treatment of STS Lung Mets
“Ongoing Phase 1b/2 Study for Treatment of STS Lung Mets Dose escalation from 210 mg to ‘a max of 450 mg (currently enrolling 390 mg) Promising Early Targeted number of Phase 1b Clinical Activity in Primary Endpoint: establish subjects: ~18 Phase 1b? MTD/RP2D and safety Treatment regimen: single dos
Slide 10: Annamycin: STS Clinical Benefit to Date
ANNAMYCIN TS: Clinical Benefit to Date’ Patients treated at (3 of 5 cohorts completed) NO Dose-limiting toxicity (DLT) experienced to-date 44% Of patients in first 3 cohorts experienced preliminary 0 clinical activity, defined as stable disease and/or better 100° Non-cardiotoxic (7 of 9 treated abov
Slide 11: Ongoing Phase 1/2 Study for Treatment of AML
“Ongoing Phase 1/2 Study for Treatment of AML Dose escalation from 120 mg to. a max of 420 mg (currently at 240mg) Topline Phase 1 Primary Endpoint: establish Results Expected safety and MTD/RP2D Qi 2022 Targeted number of Phase 1 subjects remaining to RP2D:~15 Treatment regimen: infusions days 1, 2
Slide 12: Annamycin: AML Clinical Benefit to Date
ANNAMYCIN AML Clinical Benefit to Date’ Patients’ treated in both US and EU trials 12 Patients taken above the lifetime maximum anthracycline dose established by FDA 67% Preliminary response rate in 240 mg cohort?(including a © CRi that may qualify for curative BMT) Non-cardiotoxic
Slide 13: The Full Annamycin Opportunity
The Full Annamycin Opportunity Potential for Significant Upside / antreaticiver / ‘STS Lung Mets Endometrial Lung —— 104K re licatic re 2 . 7 “olorectal Target Indications. } Acate yelid Potential Annamycin er ‘TOTAL INCIDENCE Expansion Indicati¢ 33.5K TaRaNeeeaionees TOTAL INCIDENCE coltteal dation
Slide 14: WP1122: Entering Phase 1 Study for COVID-19
WP1122: Entering Phase 1 Study for COVID-19 Key _ Highlights ED | 4 Regulatory \\ Highlights } US IND allowed for GBM Strong preclinical data for GBM and pancreatic cancer
Slide 15: Treatment of COVID-19
Treatment of COVID-19 Multiple independent University studies show antiviral preclinical activity of 2-DG against SARS-CoV-2 2-DG was just given Emergency Use Authorization for treating COVID-19 in India based on Phase 2 resultst WP1122 isa prodrug of 2-DG that has substantially higher in vitro anti
Slide 16: Follow-on Development Pipeline
Follow-on Development Pipeline Additional Follow-on Opportunities Provide Potential for Significant Upside PROGRAM INDICATION PRECLINICAL PHASE PHASE ‘UPCOMING MILESTONES ‘Annamyein Liver Mets ry IND targeted for2022 oom amp Inbraretetor 2022 Recivic inno, query Topine resus rom Phase expected H1 20
Slide 17: Financial Snapshot
Financial Snapshot Nasdaq: MBRX Strong Cash Position Funds Operations into 2024 3 Month Avg. Volume’ ®Moleculin
Slide 18: Target Value-Driving Milestones
Target Value-Driving Milestones PROGRAM INDICATION covp.19 % Initiate Phase 19 18 * 2022 ®Moleculin
Slide 19: Investment Summary
Investment Summary Advancing growing pipeline with data from multiple clinical studies expected over next 12 months Lead program, Annamycin, demonstratingsafety and @_ preliminary activity in multiple clinical studies with zero e Follow-on pipeline opportunities to fuel future growth cardiotoxicity
Slide 20: Moleculin
= Moleculin Better Treatments, More Tomorrows MOLECULIN.COM / NASDAQ: MBRX
Moleculin Biotech — Investor Presentation (January 2022) on 6ix